CKD in T2D: Contemporary Approaches to Renoprotection (June 2021)

Pre-register for this 90-minute CME/CE-certified symposium, the faculty panel will share their insights on the early diagnosis and treatment of CKD to improve renal and CV outcomes in patients with type 2 diabetes

*To participate in this symposium, you must be registered for the American Diabetes Association’s Virtual 81st Scientific Sessions.

This program is not part of the American Diabetes Association's Virtual 81st Scientific Sessions. This event is neither sponsored nor endorsed by the American Diabetes Association.


6:15 PM Welcome and Program Overview

6:20 PM CKD Overview

6:40 PM CKD Pathogenesis in Diabetes

7:05 PM CKD Treatment: Where Are We Now?

7:30 PM Question and Answer Session

7:45 PM Adjournment


Date / Time
Event Details


George L. Bakris, MD

Professor of Medicine
, American Heart Association Comprehensive Hypertension Center
Department of Medicine
University of Chicago Medicine
Chicago, Illinois

Vivian A. Fonseca, MD, FRCP

Tullis-Tulane Alumni Chair in Diabetes
Professor of Medicine
 Section of Endocrinology
Tulane University School of Medicine
New Orleans, Louisiana

Susanne Nicholas, MD, MPH, PhD

Associate Professor of Medicine
UCLA David Geffen School of Medicine
Los Angeles, California

Goal Statement
The goal of this program is to enhance the knowledge and clinical competency of physicians, advanced practice providers, nurses, pharmacists, and other healthcare professionals in the early diagnosis and treatment of CKD to improve renal and CV outcomes in patients with type 2 diabetes. 

Target Audience
This program is designed to meet the educational needs of endocrinologists (physicians and fellows), nephrologists, internists, primary care physicians, endocrine nurses, pharmacists, and advanced practice professionals who will virtually attend the American Diabetes Association's Virtual 81st Scientific Sessions and care for individuals with diabetes and CKD.

Learning Objectives

  • Implement guideline recommendations for CKD screening in patients with T2D using UACR and eGFR values
  • Describe common renal and CV outcomes associated with progressive CKD in patients with T2D
  • Summarize the role of MR activation in CKD pathogenesis and the evidence that blocking MR can provide renoprotection


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Psysicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-100-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.